March 23, 2017

To: Nebraska Healthcare providers and Public Health professionals

RE: Confirmed case of Measles with exposures in Omaha, Papillion, La Vista

From: Dr. Thomas Safranek, M.D. Blake Hendrickson, MPH
Nebraska State Epidemiologist VPD Surveillance Coordinator
Shavonna Lausterer, MPH, CPH Adi Pour, PhD
Director of Sarpy/Cass Health Director
Department of Health & Wellness Douglas County Health Department

A laboratory-confirmed case of measles has been reported to public health. A joint public health investigation by the Nebraska Department of Health and Human Services, Sarpy Cass Department of Health & Wellness, and Douglas County Health Department has identified several public exposures in Douglas and Sarpy Counties. All known persons affected have been notified. Exposures included:

- Delta flight 798 from Minneapolis to Omaha March 12, 2017 (8:00pm-10:30pm)
- Eppley Airfield South Terminal, Omaha March 12, 2017 (10:30pm – 1:30am)
- Eppley Airfield South baggage claim, Omaha March 12, 2017 (10:30pm – 1:30am)
- Hampton Inn, 12331 Southport Pkwy La Vista March 12, 2017 – March 17, 2017
- Urgent Care of Papillion, S 73rd Plaza March 15, 2017 (6:00pm – 8:30pm)
- CHI Urgent Care, S 96th St La Vista March 15, 2017 (7:00pm – 10:00pm)
- Bergan Mercy Hospital ED, Omaha March 15, 2017 (8:30pm – 12:00am)

Healthcare providers should report rash/fever illness in patients with exposures to the above venues immediately to the Nebraska Department of Health and Human Services at (402) 471-6450, or your local health department.

- **Consider measles** in patients of any age who have a fever AND a rash. Fever can spike as high as 105°F. Measles rashes are red, blotchy and maculopapular and typically start on the hairline and face and then spread downwards to the rest of the body.
- **Obtain a thorough history** on such patients, including: the above exposures or travel outside the country or contact with international travelers in the prior three weeks; and prior vaccinations for measles. Exposure to measles is defined as sharing the same air space with a person with measles (and up to 2 hours after the infected person left) during their contagious period (4 days before to 4 days after rash onset) for any period of time.
- **Non-immune individuals who were exposed**: Healthy adults and children with only 1 documented MMR should be given MMR #2. Infants 6-11 months can be given a dose of MMR if exposed to measles. See information on the table below for more information for infants under 6 months.
• **If you suspect** your patient has measles, isolate (see next page) the patient immediately and alert the state or local health department as soon as possible. The risk of measles transmission to others can be reduced if control measures are implemented quickly.

• **Laboratory Testing**: Measles IgM (may need to be repeated 72 hours after rash onset if negative); nasopharyngeal and throat swab for RT-PCR and viral culture can be organized for you by the health department.

• **Consult the health department for more information if you are ordering a measles test.**

• **Incubation period** time from exposure to onset of symptoms is usually around 14 days (range 7-21 days)

• **Establishing immunity**: Information on determining if someone is immune to measles is on the following page.

Public health authorities established a 2-dose MMR vaccine schedule (at 12-15 months and 4-6 years) in 1990, and schools established documentation of 2 doses of MMR as a criteria for school entry around that time. Most persons under 40 years of age who were compliant with school entry requirements have had two doses of MMR and have a very low risk of developing measles if exposed. Persons who were non-compliant with that requirement are at high risk if exposed to a person shedding the measles virus. All persons who have not received two doses of MMR are urged to consider vaccination at this time, especially if they were present at the times and locations specified. Exposed persons who are not immune and who refuse immunization should not attend school/work for 21 days after last exposure.

**Preventing measles transmission in healthcare settings**


**Suspected measles patients** (i.e., persons with febrile rash illness) should be removed from emergency department and clinic waiting areas as soon as they are identified, placed in a private room with the door closed, and asked to wear an N95 mask, if tolerated. In hospital settings, patients with suspected measles should be placed immediately in an airborne infection (negative-pressure) isolation room if one is available and, if possible, should not be sent to other parts of the hospital for examination or testing purposes.
Recommendations for follow-up of persons exposed to measles

† Confirm immunity (IgG+ or 2 documented doses MMR) in all exposed healthcare personnel, including those born <1957.

§ Vaccinate at the same time blood is drawn for serology.

|| Immune globulin (IG) recommended for exposed infants <1 year of age, susceptible household members who did not receive MMR <72 hours of exposure, immunocompromised persons, and susceptible pregnant women. Give priority to people who were exposed to measles in settings where they have intense, prolonged close contact (such as household, child care, classroom, etc.) Alternatively, MMR vaccine can be given instead of IGIM to infants age 6 through 11 months, if it can be given within 72 hours of exposure.

* Daily calls to exposed person to monitor for development of measles symptoms (1st exposure + 5 days through last exposure +21 days). If symptoms develop, immediately isolate through day 4 after rash onset (day of rash onset is day 0).

- Other useful resources for health care professionals
  - Centers for Disease Control and Prevention (CDC)/ Immunization Action Coalition
    - http://www.immunize.org/askexperts/experts_mmr.asp

<table>
<thead>
<tr>
<th>Category</th>
<th>IgG test</th>
<th>Vaccinate</th>
<th>*Home quarantine</th>
<th>*Active symptom monitoring</th>
<th>Passive symptom watch</th>
</tr>
</thead>
<tbody>
<tr>
<td>Born before 1957‡ (~5% will be susceptible)</td>
<td>No‡</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Born during or after 1957:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 documented doses MMR prior to measles exposure (~1% will be susceptible)</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>IgG positive (&lt;1% will be susceptible)</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>1 documented dose MMR prior to measles exposure in children aged 1-4 years and adults who are not healthcare personnel, school or college students, or international travelers (~5% will be susceptible)</td>
<td>No</td>
<td>Vaccinate (within 72 hours of exposure is most effective)</td>
<td>No</td>
<td>Yes</td>
<td>N/A</td>
</tr>
<tr>
<td>1 documented dose MMR prior to measles exposure in adults for whom 2 doses are recommended, i.e., healthcare personnel, school and college students, and international travelers (~5% will be susceptible)</td>
<td>Yes</td>
<td>Yes§</td>
<td>No</td>
<td>Yes</td>
<td>N/A</td>
</tr>
<tr>
<td>First MMR dose given &lt;72 hours of exposure</td>
<td>No</td>
<td>-</td>
<td>No</td>
<td>Yes</td>
<td>N/A</td>
</tr>
<tr>
<td>IG given &lt;6 days of exposure</td>
<td></td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Unknown status</td>
<td>Yes</td>
<td>Yes§</td>
<td>Yes</td>
<td>Yes</td>
<td>N/A</td>
</tr>
<tr>
<td>Unvaccinated/nonimmune/not given IG</td>
<td>Yes</td>
<td>Yes§</td>
<td>Yes</td>
<td>Yes</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<1957.

§ Vaccinate at the same time blood is drawn for serology.

|| Immune globulin (IG) recommended for exposed infants <1 year of age, susceptible household members who did not receive MMR <72 hours of exposure, immunocompromised persons, and susceptible pregnant women. Give priority to people who were exposed to measles in settings where they have intense, prolonged close contact (such as household, child care, classroom, etc.) Alternatively, MMR vaccine can be given instead of IGIM to infants age 6 through 11 months, if it can be given within 72 hours of exposure.

* Daily calls to exposed person to monitor for development of measles symptoms (1st exposure + 5 days through last exposure +21 days). If symptoms develop, immediately isolate through day 4 after rash onset (day of rash onset is day 0).